Investigational drug · Phase 2
BPL-003
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Treatment Resistant Depression.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
4
Any phase or sponsor naming "BPL-003"
First trial start
2023
Feb 10, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BPL-003", any sponsor or status.
Conditions studied
As listed on its trial records.
- Treatment Resistant Depression
Approved drugs for the same conditions: Depression (major depressive disorder) · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "BPL-003" as an intervention, largest first.
- BPL-003 Efficacy and Safety in Treatment Resistant DepressionPivotal-lookingCompleted
Beckley Psytech LimitedIndustry
NCT05870540 · 196 participants · Start Sep 14, 2023 · Primary completion Mar 28, 2025
Drug: BPL-003; BPL-003 · For: Treatment Resistant Depression
Sites: Birmingham, Alabama; Rogers, Arkansas; San Diego, California · 42 sites in all
Beckley Psytech LimitedIndustry
NCT05660642 · 72 participants (planned) · Start Feb 10, 2023 · Primary completion Nov 2026
Drug: BPL-003 · For: Treatment Resistant Depression
Sites: Liverpool, United Kingdom; London, United Kingdom · 3 sites in all
Beckley Psytech LimitedIndustry
NCT05347849 · 62 participants · Start Feb 14, 2022 · Primary completion Jan 19, 2024
Drug: BPL-003 · For: Pharmacokinetics in Healthy Adults
Sites: London, United Kingdom
Beckley Psytech LimitedIndustry
NCT05674929 · 13 participants · Start May 30, 2023 · Primary completion Oct 2, 2024
Drug: BPL-003 · For: Alcohol Use Disorder
Sites: London, United Kingdom · 2 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Next-Generation Pharmacotherapies for Unipolar Mood Disorders: A Leading Article on Phase II/III Drug Development Across Diverse Mechanisms.
King A, Hardy M, Rhee TG, et al. · CNS Drugs 2026
- Psychological change processes in alcohol use disorder: A qualitative study of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) with cognitive behavioural therapy.
Seynaeve M, Dunbar F, Ermakova AO, et al. · Addiction 2026
- A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine) in patients with treatment-resistant depression.
Roberts C, Seynaeve M, Ermakova AO, et al. · J Psychopharmacol 2026
- 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) for alcohol use disorder: An open-label, phase 2, proof-of-concept, clinical trial.
Marsden J, Kelleher M, Dunbar F, et al. · Addiction 2025
- Mapping the phenomenology of intranasal 5-MeO-DMT in psychedelic-naïve healthy adults.
Ermakova AO, Dunbar F, Seynaeve M, et al. · Sci Rep 2025
- Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine benzoate) in healthy participants.
Rucker JJ, Roberts C, Seynaeve M, et al. · J Psychopharmacol 2024
Also in development for Treatment Resistant Depression
- PsilocybinCOMP360Phase 34 trials
COMPASS Pathways · Treatment Resistant Depression, Major Depressive Disorder, Anorexia Nervosa
- PBOPhase 32 trials
SK Life Science, Inc. · Primary Generalized Epilepsy, Treatment Resistant Depression
- NRX-101Phase 31 trial
NeuroRx, Inc. · Treatment Resistant Depression, Treatment Resistant Depression (TRD)
- NV-5138SPN820Phase 21 trial
Navitor Pharmaceuticals, Inc. · Treatment Resistant Depression
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.